GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Thu, 17th Jun 2021 11:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Midatech Pharma PLC, up 89% at 51.90 pence, 12-month range 18.10p-87.00p. The biotechnology company says it has data demonstrating that its Q-Sphera technology can formulate monoclonal antibodies into long-acting injectables, a novel development in pharmaceuticals with significant medical and commercial potential. "The company believes no other commercial or academic organisation has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling," it says.

----------

Blue Prism Group PLC, up 7.4% at 964.50p, 12-month range 883.50p-1,900.00p. The robotic process automation firm posts narrowed interim loss after seeing growing revenue and booking numbers for the period. Blue Prism reports a pretax loss of GBP21.0 million for the six months ended April 30, sharply narrowed from GBP53.8 million a year prior. Bookings grew 35% in the first half to GBP98 million, or 39% at constant currency. Revenue for the period increased by 21% year-on-year to GBP80.4 million from GBP66.6 million, with recurring, subscription-based, licence revenue accounting for a 98% share.

----------

AIM - LOSERS

----------

Open Orphan PLC, down 14% at 30.00p, 12-month range 11.16p-34.50p. The pharmaceutical services company posts 2020 pretax loss GBP11.2 million, widened from GBP5.8 million on revenue from continuing operations of GBP20.6 million, up from GBP3.4 million. Separately, Poolbeg Pharma confirms plan to float on AIM as a spinoff of Open Orphan. Poolbeg Pharma to use IPO raise to fund clinical trial of treatment for severe influenza.

----------

Cake Box Holdings PLC, down 7.3% at 266.50p, 12-month range 155.00p-356.00p. The eggless deserts maker notes movement in shares. It confirms that it has recently emailed customers in relation to a data breach experienced in 2020 as a result of which personal and financial information may potentially have been accessed. Cake Box says it has taken the appropriate steps to investigate the incident, repair the compromised systems, and identify those customers that may have been compromised. It also has further strengthened the security of its systems to prevent future breaches, it says. "The company confirms that the data breach is not expected to have a material financial impact and as per the announcement on 12 April 2021, full year results are expected to be in line with market expectations," Cake Box adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Dec 2020 11:38

Open Orphan upbeat on progress with nasal Covid-19 vaccine

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Monday that the first in-human study of the Codagenix intranasal SARS-CoV-2 vaccine candidate for Covid-19 had gained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Read more
24 Nov 2020 16:27

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Read more
19 Nov 2020 21:18

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

Read more
5 Nov 2020 16:32

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

Read more
30 Oct 2020 11:30

Open Orphan secures new two-year contract with German client

(Sharecast News) - Pharmaceutical services company Open Orphan announced a new two-year contract with an unnamed tier 1 Germany-based pharmaceutical company on Friday.

Read more
30 Oct 2020 11:07

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Read more
20 Oct 2020 15:59

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

Read more
20 Oct 2020 09:49

Open Orphan to assist UK govt in Covid-19 study

(Sharecast News) - Pharmaceutical services company Open Orphan has signed a contract with the UK Government that will see the firm assist in the development of a Covid-19 human challenge study model to safely speed up the development of an efficacious vaccine.

Read more
16 Oct 2020 15:24

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

Read more
16 Oct 2020 08:57

Open Orphan continues talks over coronavirus challenge study

(Sharecast News) - Open Orphan updated the market on its talks with the UK government and other partners for a coronavirus challenge study in the UK on Friday, confirming that "advanced negotiations" were ongoing.

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
28 Sep 2020 19:34

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

Read more
24 Sep 2020 17:35

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

Read more
22 Sep 2020 19:35

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

Read more
22 Sep 2020 09:43

Open Orphan subsidiary wins 'important' new contract

(Sharecast News) - Pharmaceutical contract research organisation Open Orphan secured an "important" new contract to support an unnamed European client via its French subsidiary, Venn Life Sciences.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.